China NMPA Inspection - Fujian Baishiwei Medical Polymer Co., Ltd. - October 11, 2016

An unannounced inspection conducted by the Fujian Provincial Food and Drug Administration uncovered significant non-compliance at Fujian Baishiwei Medical Polymer Co., Ltd. While the precise inspection dates were not detailed in the provided information, the assessment identified critical deficiencies within the company's quality management system. Specifically, the company's operational actions were found to deviate from the stringent requirements set forth by the Good Manufacturing Practice (GMP) for medical devices. This indicates fundamental shortcomings in areas such as manufacturing processes, quality control, product testing, or documentation practices, all of which are essential for ensuring the safety, efficacy, and consistent quality of medical devices. The regulatory framework for this oversight is the Good Manufacturing Practice (GMP) for medical devices, a universally recognized standard crucial for pharmaceutical and medical device industries. As a direct consequence of these findings, Fujian Baishiwei Medical Polymer Co., Ltd. has received a formal order to promptly rectify all identified deficiencies. This mandate requires the company to implement robust corrective and preventive actions within a specified timeframe to align its operations with regulatory standards, thereby safeguarding public health and maintaining product integrity.